{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T23:03:37Z","timestamp":1789340617511,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>iNKT cells are emerging as a highly promising immunotherapy platform for the treatment of cancer. To maximise the anti-cancer activity of CAR-iNKT against the blood cancer multiple myeloma we investigated optimal CAR designs and their combination with new iNKT-specific engagers. We find that amongst five different CAR endodomains, underpinned by increased avidity and a cross talk between Plexin D1 on CAR-iNKT and Semaphorin 4\u2009A on myeloma cells, BCMA CD28z CAR-iNKT exert the highest anti-myeloma activity. Notably, CD28z CAR-iNKT outperform their CAR-T counterparts. To expand the anti-myeloma potential of CAR-iNKT, we designed and validated a high efficacy BCMA iNKT-specific engager which exerts significant anti-myeloma activity in conjunction with adoptively transferred iNKT cells. Finally, combined, dual target therapy with FCRL5 CAR-iNKT and BCMA iNKT engagers outperforms FCRL5 CAR-iNKT and limits immune escape of FCRL5-negative myeloma. Thus, optimised iNKT-based, dual-target, dual-modality immunotherapy has enhanced anti-tumor activity against multiple myeloma and potentially other malignancies.<\/jats:p>","DOI":"10.1038\/s41467-026-76718-7","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T03:13:08Z","timestamp":1786677188000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing iNKT cell immunotherapy through the integration of optimized CAR endodomains and iNKT engagers"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6618-9104","authenticated-orcid":false,"given":"Kanagaraju","family":"Ponnusamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klesti","family":"Karaxhuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4465-0457","authenticated-orcid":false,"given":"Yuchao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyra","family":"Randzavola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilia","family":"Leontari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5058-7469","authenticated-orcid":false,"given":"Bryan","family":"Lye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmood","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2213-5814","authenticated-orcid":false,"given":"Edward W.","family":"Tate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Pardalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Leonardos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nadafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogier M.","family":"Reijmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Atta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Katsarou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene AG","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1453-8576","authenticated-orcid":false,"given":"Aristeidis","family":"Chaidos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-9780","authenticated-orcid":false,"given":"Anastasios","family":"Karadimitris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"76718_CR1","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu, S. S. et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood 141, 2307\u20132315 (2023).","journal-title":"Blood"},{"key":"76718_CR2","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch, T. W. et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial. J. Clin. Oncol. 41, 1664\u20131669 (2023).","journal-title":"J. Clin. Oncol."},{"key":"76718_CR3","doi-asserted-by":"crossref","unstructured":"Jagannath, S. et al. Long-term (>\/=5-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 43, 2766\u20132771 (2025).","DOI":"10.1200\/JCO.2025.43.16_suppl.7507"},{"key":"76718_CR4","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1182\/blood-2011-11-389304","volume":"119","author":"A Chaidos","year":"2012","unstructured":"Chaidos, A. et al. Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood 119, 5030\u20135036 (2012).","journal-title":"Blood"},{"key":"76718_CR5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3389\/fimmu.2017.00900","volume":"8","author":"M Mavers","year":"2017","unstructured":"Mavers, M., Maas-Bauer, K. & Negrin, R. S. Invariant natural killer T cells as suppressors of graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Front. Immunol. 8, 900 (2017).","journal-title":"Front. Immunol."},{"key":"76718_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1084\/jem.180.3.1171","volume":"180","author":"P Dellabona","year":"1994","unstructured":"Dellabona, P., Padovan, E., Casorati, G., Brockhaus, M. & Lanzavecchia, A. An invariant V alpha 24-J alpha Q\/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells. J. Exp. Med. 180, 1171\u20131176 (1994).","journal-title":"J. Exp. Med."},{"key":"76718_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-immunol-032713-120243","volume":"32","author":"M Salio","year":"2014","unstructured":"Salio, M., Silk, J. D., Jones, E. Y. & Cerundolo, V. Biology of CD1- and MR1-restricted T cells. Annu. Rev. Immunol. 32, 323\u2013366 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"76718_CR8","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3389\/fimmu.2013.00409","volume":"4","author":"S Fujii","year":"2013","unstructured":"Fujii, S. et al. NKT cells as an ideal anti-tumor immunotherapeutic. Front. Immunol. 4, 409 (2013).","journal-title":"Front. Immunol."},{"key":"76718_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.it.2007.05.008","volume":"28","author":"M Terabe","year":"2007","unstructured":"Terabe, M. & Berzofsky, J. A. NKT cells in immunoregulation of tumor immunity: a new immunoregulatory axis. Trends Immunol. 28, 491\u2013496 (2007).","journal-title":"Trends Immunol."},{"key":"76718_CR10","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1172\/JCI37869","volume":"119","author":"L Song","year":"2009","unstructured":"Song, L. et al. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. J. Clin. Investig. 119, 1524\u20131536 (2009).","journal-title":"J. Clin. Investig."},{"key":"76718_CR11","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.celrep.2018.02.058","volume":"22","author":"F Cortesi","year":"2018","unstructured":"Cortesi, F. et al. Bimodal CD40\/Fas-dependent crosstalk between iNKT cells and tumor-associated macrophages impairs prostate cancer progression. Cell Rep. 22, 3006\u20133020 (2018).","journal-title":"Cell Rep."},{"key":"76718_CR12","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","volume":"113","author":"E Spanoudakis","year":"2009","unstructured":"Spanoudakis, E. et al. Regulation of multiple myeloma survival and progression by CD1d. Blood 113, 2498\u20132507 (2009).","journal-title":"Blood"},{"key":"76718_CR13","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.ccell.2018.08.017","volume":"34","author":"A Rotolo","year":"2018","unstructured":"Rotolo, A. et al. Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting. Cancer Cell 34, 596\u2013610 (2018).","journal-title":"Cancer Cell"},{"key":"76718_CR14","doi-asserted-by":"crossref","unstructured":"Li, Y. R. et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat. Biotechnol. 43, 329\u2013344 (2025).","DOI":"10.1038\/s41587-024-02226-y"},{"key":"76718_CR15","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1158\/1078-0432.CCR-21-1329","volume":"27","author":"F Simonetta","year":"2021","unstructured":"Simonetta, F. et al. Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming. Clin. Cancer Res. 27, 6054\u20136064 (2021).","journal-title":"Clin. Cancer Res."},{"key":"76718_CR16","doi-asserted-by":"publisher","first-page":"eabn6563","DOI":"10.1126\/sciimmunol.abn6563","volume":"7","author":"G Delfanti","year":"2022","unstructured":"Delfanti, G. et al. TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells. Sci. Immunol. 7, eabn6563 (2022).","journal-title":"Sci. Immunol."},{"key":"76718_CR17","doi-asserted-by":"crossref","unstructured":"Ren, H. et al. Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia. Blood 147, 180\u2013196 (2026).","DOI":"10.1182\/blood.2025029302"},{"key":"76718_CR18","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jtct.2023.12.072","volume":"30","author":"CC Ramos","year":"2024","unstructured":"Ramos, C. C. et al. Off-the-shelf CD19-specific CAR-NKT cells in patients with relapsed or refractory B-cell malignancies. Transplant. Cell. Ther. 30, S41\u2013S42 (2024).","journal-title":"Transplant. Cell. Ther."},{"key":"76718_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.iotech.2020.09.001","volume":"8","author":"J Feucht","year":"2020","unstructured":"Feucht, J. & Sadelain, M. Function and evolution of the prototypic CD28zeta and 4-1BBzeta chimeric antigen receptors. Immunooncol. Technol. 8, 2\u201311 (2020).","journal-title":"Immunooncol. Technol."},{"key":"76718_CR20","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","volume":"19","author":"RO Carpenter","year":"2013","unstructured":"Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048\u20132060 (2013).","journal-title":"Clin. Cancer Res."},{"key":"76718_CR21","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","volume":"604","author":"RC Larson","year":"2022","unstructured":"Larson, R. C. et al. CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours. Nature 604, 563\u2013570 (2022).","journal-title":"Nature"},{"key":"76718_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","volume":"40","author":"MB Leick","year":"2022","unstructured":"Leick, M. B. et al. Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia. Cancer Cell 40, 494\u2013508 (2022).","journal-title":"Cancer Cell"},{"key":"76718_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fernandez de Larrea","year":"2020","unstructured":"Fernandez de Larrea, C. et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 1, 146\u2013154 (2020).","journal-title":"Blood Cancer Discov."},{"key":"76718_CR24","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.celrep.2019.01.041","volume":"26","author":"G Monaco","year":"2019","unstructured":"Monaco, G. et al. RNA-seq signatures normalized by mRNA abundance allow absolute deconvolution of human immune cell types. Cell Rep. 26, 1627\u20131640 (2019).","journal-title":"Cell Rep."},{"key":"76718_CR25","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/j.cell.2018.10.022","volume":"175","author":"BJ Schmiedel","year":"2018","unstructured":"Schmiedel, B. J. et al. Impact of genetic polymorphisms on human immune cell gene expression. Cell 175, 1701\u20131715 (2018).","journal-title":"Cell"},{"key":"76718_CR26","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/art.40915","volume":"71","author":"T Carvalheiro","year":"2019","unstructured":"Carvalheiro, T. et al. Induction of inflammation and fibrosis by semaphorin 4A in systemic sclerosis. Arthritis Rheumatol. 71, 1711\u20131722 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"76718_CR27","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/nri3545","volume":"13","author":"A Kumanogoh","year":"2013","unstructured":"Kumanogoh, A. & Kikutani, H. Immunological functions of the neuropilins and plexins as receptors for semaphorins. Nat. Rev. Immunol. 13, 802\u2013814 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"76718_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ydbio.2010.09.008","volume":"349","author":"CM Gay","year":"2011","unstructured":"Gay, C. M., Zygmunt, T. & Torres-Vazquez, J. Diverse functions for the semaphorin receptor PlexinD1 in development and disease. Dev. Biol. 349, 1\u201319 (2011).","journal-title":"Dev. Biol."},{"key":"76718_CR29","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/sj.emboj.7601589","volume":"26","author":"T Toyofuku","year":"2007","unstructured":"Toyofuku, T. et al. Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. EMBO J. 26, 1373\u20131384 (2007).","journal-title":"EMBO J."},{"key":"76718_CR30","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood.2021015161","volume":"139","author":"GSF Anderson","year":"2022","unstructured":"Anderson, G. S. F. et al. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. Blood 139, 2471\u20132482 (2022).","journal-title":"Blood"},{"key":"76718_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41392-023-01702-2","volume":"9","author":"Z Yu","year":"2024","unstructured":"Yu, Z. et al. Fc receptor-like 5 (FCRL5)-directed CAR-T cells exhibit antitumor activity against multiple myeloma. Signal Transduct. Target. Ther. 9, 16 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"76718_CR32","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li, J. et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell 31, 383\u2013395 (2017).","journal-title":"Cancer Cell"},{"key":"76718_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39395-4","volume":"14","author":"D Jiang","year":"2023","unstructured":"Jiang, D. et al. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat. Commun. 14, 3642 (2023).","journal-title":"Nat. Commun."},{"key":"76718_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","volume":"28","author":"Z Zhao","year":"2015","unstructured":"Zhao, Z. et al. Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells. Cancer Cell 28, 415\u2013428 (2015).","journal-title":"Cancer Cell"},{"key":"76718_CR35","doi-asserted-by":"publisher","first-page":"1035276","DOI":"10.3389\/fimmu.2022.1035276","volume":"13","author":"J Wei","year":"2022","unstructured":"Wei, J., Yang, Y., Wang, G. & Liu, M. Current landscape and future directions of bispecific antibodies in cancer immunotherapy. Front. Immunol. 13, 1035276 (2022).","journal-title":"Front. Immunol."},{"key":"76718_CR36","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"76718_CR37","doi-asserted-by":"crossref","unstructured":"Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci Signal. 11, eaat6753 (2018).","DOI":"10.1126\/scisignal.aat6753"},{"key":"76718_CR38","doi-asserted-by":"crossref","unstructured":"Philipson, B. I. et al. 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-kappaB signaling. Sci Signal. 13, eaay8248 (2020).","DOI":"10.1126\/scisignal.aay8248"},{"key":"76718_CR39","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.immuni.2008.10.008","volume":"29","author":"YI Choi","year":"2008","unstructured":"Choi, Y. I. et al. PlexinD1 glycoprotein controls migration of positively selected thymocytes into the medulla. Immunity 29, 888\u2013898 (2008).","journal-title":"Immunity"},{"key":"76718_CR40","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature12428","volume":"501","author":"GM Delgoffe","year":"2013","unstructured":"Delgoffe, G. M. et al. Stability and function of regulatory T cells is maintained by a neuropilin-1-semaphorin-4a axis. Nature 501, 252\u2013256 (2013).","journal-title":"Nature"},{"key":"76718_CR41","doi-asserted-by":"publisher","first-page":"eade0718","DOI":"10.1126\/sciadv.ade0718","volume":"9","author":"Y Naito","year":"2023","unstructured":"Naito, Y. et al. Tumor-derived semaphorin 4A improves PD-1-blocking antibody efficacy by enhancing CD8(+) T cell cytotoxicity and proliferation. Sci. Adv. 9, eade0718 (2023).","journal-title":"Sci. Adv."},{"key":"76718_CR42","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/nature01037","volume":"419","author":"A Kumanogoh","year":"2002","unstructured":"Kumanogoh, A. et al. Class IV semaphorin Sema4A enhances T-cell activation and interacts with Tim-2. Nature 419, 629\u2013633 (2002).","journal-title":"Nature"},{"key":"76718_CR43","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau, H. et al. International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J. Clin. Oncol. 43, 2739\u20132751 (2025).","journal-title":"J. Clin. Oncol."},{"key":"76718_CR44","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","volume":"5","author":"X Zhou","year":"2024","unstructured":"Zhou, X. et al. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat. Cancer 5, 1607\u20131621 (2024).","journal-title":"Nat. Cancer"},{"key":"76718_CR45","doi-asserted-by":"publisher","first-page":"1102471","DOI":"10.3389\/fimmu.2022.1102471","volume":"13","author":"C Giannotta","year":"2022","unstructured":"Giannotta, C., Autino, F. & Massaia, M. The immune suppressive tumor microenvironment in multiple myeloma: the contribution of myeloid-derived suppressor cells. Front. Immunol. 13, 1102471 (2022).","journal-title":"Front. Immunol."},{"key":"76718_CR46","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","volume":"31","author":"Y Nieto","year":"2025","unstructured":"Nieto, Y. et al. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat. Med. 31, 1987\u20131993 (2025).","journal-title":"Nat. Med."},{"key":"76718_CR47","doi-asserted-by":"publisher","first-page":"100961","DOI":"10.1016\/j.xcrm.2023.100961","volume":"4","author":"R Lameris","year":"2023","unstructured":"Lameris, R. et al. A bispecific T cell engager recruits both type 1 NKT and Vgamma9Vdelta2-T cells for the treatment of CD1d-expressing hematological malignancies. Cell Rep. Med. 4, 100961 (2023).","journal-title":"Cell Rep. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76718-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76718-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T22:27:10Z","timestamp":1789338430000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76718-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76718"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76718-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K. and K.P. report holding options\/shares in Arovella Therapeutics Ltd. The rest of the authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9755"}}